# PHAXIAM Therapeutics

formed in 2023 from Pherecydes' merger with Erytech, PHAXIAM aimed to build a 35-45-phage GMP bank covering the most critical resistant pathogens by end-2026, with commercial IV and orthopedic-infection programs.…


Source: https://en.bioecon.ru/companies/phaxiam-therapeutics/
Updated: 2026-08-15

- Country: France

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | €7.8 million capital increase settled in July 2024 | https://live.euronext.com/en/products/equities/company-news/2025-01-31-phaxiam-provides-update-deployment-its-strategy-maximize, https://www.globenewswire.com/news-release/2024/09/25/2953185/0/en/PHAXIAM-Provides-Business-and-Financial-Update-For-the-First-Half-of-2024.html |
| Capacity | Aiming for a portfolio of 25 GMP phages by end-2025 and 35-45 GMP phages by end-2026 | https://live.euronext.com/en/products/equities/company-news/2025-01-30-phaxiam-therapeutics-and-technophage-enter-strategic, https://live.euronext.com/en/products/equities/company-news/2025-01-31-phaxiam-provides-update-deployment-its-strategy-maximize, https://www.businesswire.com/news/home/20250130268564/en/PHAXIAM-Provides-An-Update-On-The-Deployment-Of-Its-Strategy-To-Maximize-The-Development-Potential-Of-Phage-Therapy |
| Regulatory approval | IND approval from US FDA in Q4 2024 for the GLORIA study | https://live.euronext.com/en/products/equities/company-news/2025-01-31-phaxiam-provides-update-deployment-its-strategy-maximize, https://www.businesswire.com/news/home/20250130268564/en/PHAXIAM-Provides-An-Update-On-The-Deployment-Of-Its-Strategy-To-Maximize-The-Development-Potential-Of-Phage-Therapy, https://www.globenewswire.com/news-release/2024/09/25/2953185/0/en/PHAXIAM-Provides-Business-and-Financial-Update-For-the-First-Half-of-2024.html |
| Production site | Headquarters in Lyon, France; collaboration with Technophage for manufacturing | https://prospeo.io/c/phaxiam-therapeutics |
| Headcount | Estimated between 32 and 100 employees [medium confidence] | https://prospeo.io/c/phaxiam-therapeutics |
| Revenue | Targeting €20 million in revenue in 2027 | https://live.euronext.com/en/products/equities/company-news/2025-01-31-phaxiam-provides-update-deployment-its-strategy-maximize, https://www.businesswire.com/news/home/20250130268564/en/PHAXIAM-Provides-An-Update-On-The-Deployment-Of-Its-Strategy-To-Maximize-The-Development-Potential-Of-Phage-Therapy |

Independent sources: businesswire.com, globenewswire.com, live.euronext.com, prospeo.io

## Technologies

- [Bacteriophage therapy](https://en.bioecon.ru/technology/bacteriophage-therapy/)